Evelyn Tomaszewski

Suggest Changes
Learn More
2548 Background: Nontoxic immunologic targeting strategies for the treatment of metastatic breast cancer (MBC) are needed. Anti-CD3 activated T cells (ATC) retargeted (armed) with anti-CD3 x(More)
  • 1